Altre lingue Tango Therapeutics, Inc.

Azioni

TNGX

US87583X1090

Tempo reale stimato Cboe BZX Altri mercati azionari 16:16:03 26/04/2024			Variaz. 5gg	Var. 1 gen.
7,5 ^USD	+2,32%		+0,27%	-25,96%

04/04	TANGO THERAPEUTICS, INC. : il giudizio da Cantor Fitzgerald è ora al rialzo	ZM
21/03	TANGO THERAPEUTICS, INC. : prospettiva positiva di HC Wainwright	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

British billionaire Joe Lewis fined $5 million by US judge for insider trading	04/04
Multibillionaire Joe Lewis to face US sentencing for insider trading	04/04
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M	18/03
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights	18/03
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index	18/03
Tango Therapeutics to Participate in Upcoming Investor Conferences	06/03
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024	05/03
Tango Therapeutics to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	31/01
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	24/01
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/01
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04/01
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study	04/01
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348	03/01
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers	03/01
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Tng348 in Patients with Brca1/2-Mutant and Other Hrd+ Cancers	03/01
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting	13/11
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Tango Therapeutics, Inc.

Azioni

TNGX

US87583X1090

Altre lingue

Filtri